LAVAL, QC / ACCESSWIRE / May 15, 2024 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) today announced the results of its 2024 annual meeting of shareholders.
Annual Meeting Results
The 10 directors nominated at the Company's 2024 annual meeting of shareholders held on May 14, 2024, were elected by a vote of the shareholders. The detailed results of the vote for the election of directors are set out below:
Name | For | Withheld | Broker Non-Votes | |||||||||
Thomas J. Appio | 181,373,219 | 10,918,741 | 70,931,303 | |||||||||
Christian A. Garcia | 181,143,285 | 11,148,675 | 70,931,303 | |||||||||
Brett M. Icahn | 170,144,670 | 22,147,290 | 70,931,303 | |||||||||
Sarah B. Kavanagh | 180,316,464 | 11,975,496 | 70,931,303 | |||||||||
Frank D. Lee | 173,147,642 | 19,144,318 | 70,931,303 | |||||||||
Steven D. Miller | 177,700,669 | 14,591,291 | 70,931,303 | |||||||||
Richard C. Mulligan, Ph.D. | 175,256,854 | 17,035,106 | 70,931,303 | |||||||||
John A. Paulson | 179,422,691 | 12,869,269 | 70,931,303 | |||||||||
Robert N. Power | 173,228,670 | 19,063,290 | 70,931,303 | |||||||||
Amy B. Wechsler, M.D. | 181,626,477 | 10,665,483 | 70,931,303 | |||||||||
At the annual meeting of shareholders, shareholders also approved, in a non-binding advisory vote, the compensation of the Company's named executive officers, an amendment to the Company's 2014 Omnibus Incentive Plan to increase the number of common shares authorized for issuance thereunder, and appointed PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm until the close of the Company's 2025 annual meeting of shareholders.
For the purposes of Toronto Stock Exchange (TSX) approval with respect to the Plan, the Company relied on the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible inter-listed issuers on a recognized exchange, such as the NYSE.
The final vote tabulation on all matters voted on at the meeting will be reported to the U.S. Securities and Exchange Commission on a current report on Form 8-K, and such report will be made available on the Company's SEDAR profile and on the Company's website at www.bauschhealth.com.
About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health, through our controlling ownership of Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information, visit www.bauschhealth.com and connect with us on LinkedIn.
Investor Contact:
Garen Sarafian
This email address is being protected from spambots. You need JavaScript enabled to view it.
(877) 281-6642 (toll free)
Media Contact:
Kevin Wiggins
This email address is being protected from spambots. You need JavaScript enabled to view it.
(908) 541-3785
| Last Trade: | US$7.95 |
| Daily Change: | -0.12 -1.49 |
| Daily Volume: | 884,459 |
| Market Cap: | US$2.920B |
October 30, 2024 October 27, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
